Skip to main content

Table 2 Patients’ characteristics

From: Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials

Total Number 140a
Age (years)
 Median (range) 68 (34–85)
  No. %
Sex
 Female 76 54.3
 Male 64 45.7
ECOG PS
 0 108 77.1
 1 24 17.1
 2 8 5.7
Cancer type
 Non-small-cell lung cancer 57 40.7
 Ovarian cancer 28b 20.0
 Endometrial cancer 22b 14.7
 Small-cell lung cancer 20 14.3
 Cervical cancer 7 5.0
 Thymoma/thymic carcinoma 3 2.1
 Others 4 2.9
Carboplatin dose
 AUC 6 mg/mL/min 73 52.1
 AUC 5 mg/mL/min 66 47.1
 AUC 4 mg/mL/min 1 0.7
Additional anticancer drugs
 Paclitaxel 58 41.4
 Paclitaxel+Pembrolizumab 2 1.4
 Paclitaxel+Bevacizumab+Atezolizumab 2 1.4
 Nab-Paclitaxel 2 1.4
 Nab-Paclitaxel+Pembrolizumab 4 2.9
 Pemetrexed 10 7.1
 Pemetrexed+Pembrolizumab 4 2.9
 Pemetrexed+Bevacizumab 3 2.1
 Etoposide 10 7.1
 Etoposide+Atezolizumab 2 1.4
 Vinorelbine 5 3.6
 S-1 3 2.1
 Docetaxel 2 1.4
NK1RA inclusive regimen
 Yes 90 64.3
 No 50 35.7
Habitual alcohol consumption
 Yes 50 35.7
 No 90 64.3
Motion sickness
 Yes 57 40.7
 No 83 59.3
Morning sickness
 Yes 45 32.1
 No 55 39.3
 Unknown 40 28.6
  1. a Percentages may not add up to 100 because of rounding off
  2. b One patient had comorbidities of ovarian and endometrial cancer
  3. ECOG PS Eastern Cooperative Oncology Group performance status; AUC area under the curve; S-1 tegafur plus gimeracil plus oteracil potassium.